Smith & Nephew and OrthoSensor to co-market VERASENSE™ Sensor Assisted Surgery
with JOURNEY™ II and LEGION™ Total Knee Replacements
LONDON, March 10, 2014
LONDON, March 10, 2014 /PRNewswire/ -- Smith & Nephew (NYSE:SNN;LSE:SN), the
global medical technology business, and OrthoSensor, the leader in intelligent
orthopaedics, announced today an agreement that will enable surgeons to
benefit from OrthoSensor's VERASENSE Sensor Assisted Surgery Technology for
soft tissue balancing when implanting Smith & Nephew's JOURNEY™ II and LEGION™
Total Knee Systems.
Smith & Nephew logo
VERASENSE utilizes advanced sensor technologies to enable evidence-based
surgical decisions regarding component position, limb alignment and soft
tissue balance to optimize outcomes in total knee replacement. Research shows
that patients whose knees have been balanced with the VERASENSE Knee System
report less pain and experience greater improvements in function, activity
levels and satisfaction post-operatively. ^ 1
"Proper alignment and soft-tissue balance are vital to achieving favorable
biomechanics in total knee replacement procedures," said Dr. Steven Haas,
Chief of the Knee Service at New York's Hospital for Special Surgery.
"VERASENSE not only allows me to verify the benefits of newer knee designs, it
also helps ensure proper knee balance, which leads to a more normal feeling
knee and a return to the active lifestyle these patients desire."
"Our JOURNEY II Total Knee System with VERILAST™ Technology is already
delivering improved knee motion, patient function and implant wear
reduction^2," said Gaurav Agarwal, President of Orthopaedic Reconstruction for
Smith & Nephew. "By combining our innovations with VERASENSE's exacting
component placement and soft-tissue balancing our surgeons can deliver even
more benefits to patients."
Historically, soft tissue balancing has been accomplished by subjective
surgeon feel. The VERASENSE Knee System now provides surgeons with real-time,
quantitative data that enables evidence-based, intraoperative decisions
regarding component position, limb alignment and soft tissue releases to
achieve balance and stability through a full range of motion. At one-year,
97% of patients whose knees were quantifiably balanced using the VERASENSE
Knee System said they were 'satisfied' to 'very satisfied' with the outcome of
their total knee arthroplasty (TKA), a marked improvement over the average 81%
satisfaction reported in literature.^3
Jay Pierce, President and CEO of OrthoSensor, added, "We are seeing promising
improvements in clinical outcomes and patient satisfaction in a multi-center
study tracking patients balanced with VERASENSE. We are pleased to work with
Smith & Nephew to enable more surgeons to better treat their patients with our
technology and the JOURNEY II and LEGION Total Knee Systems."
^1Gustke K, Golladay G, Roche M, Elson L, Anderson C. New Method for Defining
Balance: Promising Short-Term Clinical Outcomes of Sensor-Guided TKA. J
Arthroplasty. 2013 Oct 24. pii: S0883-5403(13)00802-4. doi:
10.1016/j.arth.2013.10.020. [Epub ahead of print]
^2Catani F, Ensini A, Belvedere C, Feliciangeli A, Benedetti MG, Leardini A,
Giannini S. In vivo kinematics and kinetics of a bi-cruciate substituting
total knee arthroplasty: a combined fluoroscopic and gait analysis study. J
Orthop Res. 2009 Dec;27(12):1569-75.
^3OrthoSensor Multicenter Evaluation 1-Year Results (pending publication).
About VERILAST Technology
VERILAST Technology is a unique combination of two advanced, wear-reducing
materials: Smith & Nephew's award-winning OXINIUM™ Oxidized Zirconium, a
ceramicised metal alloy, and a "cross-linked" plastic component (XLPE).
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping
healthcare professionals improve people's lives. With leadership positions in
Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and
Trauma & Extremities, Smith & Nephew has around 11,000 employees and a
presence in more than 90 countries. Annual sales in 2013 were more than $4.3
billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).
For more information about Smith & Nephew, please visit our corporate website
www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit
SmithNephewplc on Facebook.com
OrthoSensor, Inc. develops and commercializes intelligent orthopaedic devices
and data services that provide quantitative feedback to surgeons and
hospitals. The company's intelligent orthopaedic devices utilize advanced
proprietary sensor and communications technologies coupled with the company's
innovative software products to enable evidence-based orthopaedic surgery and
a vision of improving patient outcomes and reducing the cost of treating
musculoskeletal disease. For more information about OrthoSensor or the
VERASENSE Knee System, please visit: www.orthosensor.com.
This document may contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth and
trading margins, market trends and our product pipeline are forward-looking
statements. Phrases such as "aim", "plan", "intend", "anticipate",
"well-placed", "believe", "estimate", "expect", "target", "consider" and
similar expressions are generally intended to identify forward-looking
statements. Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual results to
differ materially from what is expressed or implied by the statements. For
Smith & Nephew, these factors include: economic and financial conditions in
the markets we serve, especially those affecting health care providers, payers
and customers; price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals, reimbursement
decisions or other government actions; product defects or recalls; litigation
relating to patent or other claims; legal compliance risks and related
investigative, remedial or enforcement actions; strategic actions, including
acquisitions and dispositions, our success in performing due diligence,
valuing and integrating acquired businesses; disruption that may result from
transactions or other changes we make in our business plans or organisation to
adapt to market developments; and numerous other matters that affect us or our
markets, including those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith & Nephew has
filed with the U.S. Securities and Exchange Commission under the U.S.
Securities Exchange Act of 1934, as amended, including Smith & Nephew's most
recent annual report on Form 20-F, for a discussion of certain of these
factors. Any forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or oral
forward-looking statements attributable to Smith & Nephew are qualified by
this caution. Smith & Nephew does not undertake any obligation to update or
revise any forward-looking statement to reflect any change in circumstances or
in Smith & Nephew's expectations.
™Trademark of Smith & Nephew. Registered US Patent and Trademark Office.
OrthoSensor and VERASENSE are trademarks of OrthoSensor, Inc. Registered US
Patent and Trademark Office.
SOURCE Smith & Nephew
Contact: Media, Joe Metzger, Smith & Nephew, +1 (978) 749-1330, Brandy Krier,
OrthoSensor, Inc., +1 (954) 604-4540; Investor/Analyst, Phil Cowdy, Smith &
Nephew, +44 (0)20 7401 7646
Press spacebar to pause and continue. Press esc to stop.